Drugs that contain Lamivudine; Raltegravir Potassium
1. Dutrebis patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7820660 | MERCK SHARP DOHME | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Apr, 2023
(7 months ago) | |
| US7169780 | MERCK SHARP DOHME | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Oct, 2023
(2 months ago) | |
| US7754731 | MERCK SHARP DOHME | Potassium salt of an HIV integrase inhibitor |
Mar, 2029
(5 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7435734 | MERCK SHARP DOHME | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Oct, 2022
(1 year, 1 month ago) | |
| US7217713 | MERCK SHARP DOHME | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Oct, 2022
(1 year, 1 month ago) | |
|
US7217713 (Pediatric) | MERCK SHARP DOHME | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Apr, 2023
(7 months ago) | |
|
US7435734 (Pediatric) | MERCK SHARP DOHME | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Apr, 2023
(7 months ago) | |
|
US7169780 (Pediatric) | MERCK SHARP DOHME | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Apr, 2024
(3 months from now) | |
|
US7754731 (Pediatric) | MERCK SHARP DOHME | Potassium salt of an HIV integrase inhibitor |
Sep, 2029
(5 years from now) | |
Market Authorisation Date: 06 February, 2015
Treatment: Treatment of hiv-1 infection
Dosage: TABLET;ORAL
More Information on Dosage
DUTREBIS family patents
